Obesity Treatments Have Changed. Now Care Delivery Has to Catch Up

In a recent discussion, a self-insured employer told me that referrals to their existing weight-management programs had nearly tripled in a single year. I congratulated them. Then they told me the outcomes they were tracking hadn't moved. That conversation has stayed with me: the treatment modalities have never worked better, but we have never been more at risk of using them without the care model required to make their benefits last.

The arrival of GLP-1 medications has done something we spent decades arguing for. It has forced the system to treat obesity as what it is– a chronic, metabolic disease, not a failure of willpower. Nearly two in five American adults live with obesity. For decades, the math was stark: surgery could deliver 25 to 35 percent total body weight loss; medications, maybe 5. Today’s therapies reach 15 to 20 percent. Surgery hasn’t been dethroned; but, for the first time, medicine has two powerful tools instead of one. That is a genuine breakthrough. But a breakthrough in pharmacology is not the same as a breakthrough in care. GLP-1s did not create the operating problem in obesity care; they exposed it.

Here is the uncomfortable truth I share with finance and clinical leaders: a prescription is not a program. When medication is handed to a patient without the scaffolding around it—nutrition, behavioral support, muscle preservation and a plan for what happens when treatment changes or ends—the outcome can be fragile rather than durable. Patients may lose muscle along with fat, struggle to get the right nutrition, discontinue treatment and regain weight when therapy stops. In some cases, they can end up back near baseline with less lean mass and a much harder road ahead. And the employer, payer or member who funded that treatment is left with rising costs and too little lasting benefit to show for it.

That is the challenge the field must solve and it comes down to three operating requirements.

The first is matching. Obesity care is not a single-modality journey. Some patients do well with behavioral intervention alone; others need pharmacotherapy, surgery or a combination that changes over time. The operating model has to identify the right intervention for the right patient and make it easy to move to the next level of care when the clinical picture changes.

A prescription is not a program.

The second is continuity. Today, bariatric surgery, medical weight management, primary care and employer-sponsored programs often operate as separate silos. Patients can linger on a therapy that is no longer working or be left to navigate the next step alone. Comprehensive care requires an explicit handoff between modalities, with the patient supported through each transition rather than asked to start over.

The third is accountability. As utilization grows, employers, payers and health systems need to know whether spend is producing durable clinical and economic value. That means measuring more than prescriptions written or program enrollment. It means following outcomes across the longitudinal pathway and understanding whether patients are receiving the right care, staying engaged and improving over time.

The new medications have expanded what is clinically possible - now the care model has to catch up! None of this is an argument against the new medications. They have expanded what is clinically possible.

The opportunity ahead is comprehensive metabolic care: one connected pathway that stays with the patient over time, not a twelve-week program or another point solution. It means meeting each patient with the right intervention at the right time—medication when medication is right, surgery when surgery is right and behavioral support throughout—in whatever combination their disease and life demand and adjusting that approach when they are not responding. It means helping patients move through complex pathways, including navigating surgery more efficiently, while embedding care within the clinicians’ existing workflows and clinical record. Most importantly, it means measuring success by durable outcomes, not prescriptions written or programs completed. That is how employers, payers and health systems can be confident that the dollars invested today will still produce meaningful clinical and economic value years from now—and it is an impact we can measure and prove.

Operationally, that requires an orchestration layer that connects longitudinal data across the care journey, identifies when a patient should stay the course or change modalities, supports transitions among lifestyle intervention, pharmacotherapy and surgery and returns that information to the clinical workflow. The technology should make the pathway easier to manage; it should not become another destination that patients or clinicians have to navigate.

At Minerra, this is the operating model we have built - longitudinal, clinically integrated and accountable for outcomes.